I. Pyott's departure as Chief Executive Officer of Pliant Therapeutics, Inc. was reported; the filing names no successor. As of November 6, 2026, Pliant Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 17, 2026 to July 13, 2026, naming 1 appointment and 3 departures (Form 8-K, April 17, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Pliant Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Pliant Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-17 to 2026-07-13. They name 4 people, with 1 appointment and 3 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Pliant Therapeutics, Inc. files it.
Also on the record for Pliant Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 8.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Kenneth Griffin | 3.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 0.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 3.3% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by Kenneth Griffin | 5% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by Kenneth Griffin | 4.9% of the class | 5%+ stakes | Source |
| January 22, 2026 | Stake report, Schedule 13G, by Kenneth Griffin | 4.9% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 0.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Woodline Partners LP | 7.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | — | 5%+ stakes | Source |
| September 4, 2025 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 6.7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 6.43% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pliant Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Pliant Therapeutics, Inc. and the records around it.
Pliant Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
Watch Pliant Therapeutics, Inc.
Get an email when Pliant Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pliant Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Pliant Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pliant Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-13 | In | 8-K, 2026-07-13 | |||
| 2026-04-17 | Out | Chief Executive Officer | 8-K, 2026-04-17 | ||
| 2026-04-17 | Out | Chief Executive Officer | 8-K, 2026-04-17 | ||
| 2026-04-17 | Out | Chief Executive Officer | 8-K, 2026-04-17 |
Who leads Pliant Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: I. Pyott, departure reported (filed 2026-04-17). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Pliant Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Pliant Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Pliant Therapeutics, Inc.Every change, in the filing's words
Appointed: Robert Iannone
The Board also appointed Dr. Iannone to serve as a member of the Research and Development Committee of the Board (the "R&D Committee") and Dr. Borellini to serve as chairperson of the R&D Committee upon the recommendation of the Nominating and Governance Committee.
- On July 9, 2026 (the "Effective Date"), the Board of Directors (the "Board") of Pliant Therapeutics, Inc. (the "Company") increased the authorized size of the Board from seven to nine members, and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating and Corporate Governance Committee"), appointed each of Robert Iannone, M.D., M.S.C.E. as a Class I director, and Flavia Borellini, Ph.D. as a Class II director, to fill the newly-created vacancies.
- The Board has determined that both Dr. Iannone and Dr. Borellini qualify as independent directors and are qualified to serve under the applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") and the listing rules of The Nasdaq Stock Market LLC.
- Iannone and Borellini will receive an annual retainer of $40,000 starting on the Effective Date, with payment pro-rated for any partial period of service.
- In addition, Dr. Iannone will receive an annual retainer of $7,500 for his service as a member of the R&D Committee, with payment pro-rated for any partial period of service, and Dr. Borellini will receive an annual retainer of $15,000 for her service as chairperson of the R&D Committee, with payment pro-rated for any partial period of service.
Departing: I. Pyott, Chief Executive Officer
(b) Departure of Directors On April 14, 2026, David E.I. Pyott, a Class I director on the Board of Directors (the "Board") of Pliant Therapeutics, Inc. (the "Company") and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and Chair of the Nominating and Corporate Governance Committee of his retirement from the Board and all committees thereof, effective as of the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting").
Departing: Katharine Knobil, Chief Executive Officer
On April 16, 2026, Katharine Knobil, M.D., a Class II director on the Board and the Chair of the Research and Development Committee and a member of the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and Chair of the Nominating and Corporate Governance Committee of her retirement from the Board and all committees thereof, effective as of the Annual Meeting.
Departing: Suzanne Bruhn, Chief Executive Officer
On April 16, 2026, Suzanne Bruhn, Ph.D., a Class III director on the Board and a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and Chair of the Nominating and Corporate Governance Committee of her intention not to stand for reelection at the Annual Meeting and her retirement from the Board and all committees thereof, effective as of the Annual Meeting.
- Mr. Pyott's decision to retire from the Board was not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, or practices.
- Dr. Knobil's decision to retire from the Board was not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, or practices.
- Dr. Bruhn's decision not to stand for reelection and to retire from the Board was not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, or practices.
- The Board thanks each of Mr. Pyott, Dr. Knobil, and Dr. Bruhn for their years of service to the Company and its stockholders.
- (e) Repricing of Underwater Stock Options On April 15, 2026, upon the recommendation of its Compensation Committee, the Board approved an option repricing (the "Repricing"), effective as of April 17, 2026 (the "Effective Date").
- The Repricing was undertaken in accordance with, and as permitted by, the Company's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), and 2022 Inducement Plan, as amended (the "2022 Plan").
Tools for this story
Each opens in a new tab, filled in for Pliant Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.